Keynote 0241/29/2024 It demonstrated that pembrolizumab monotherapy was superior to platinum‐based chemotherapy in the first‐line setting. This study enrolled patients with previously untreated NSCLC who had a PD‐L1 tumor proportion score (TPS) ≥ 50%. The first randomized, phase III study comparing the efficacy of pembrolizumab monotherapy and platinum‐based chemotherapy is KEYNOTE‐024. Previous clinical trials have shown that pembrolizumab monotherapy more effectively improved the OS of advanced NSCLC patients without programmed death‐ligand 1 (PD‐L1) expression and oncogenic epidermal growth factor receptor ( EGFR), or anaplastic lymphoma kinase ( ALK) mutations compared with platinum‐based chemotherapy.Īdditionally, pembrolizumab in combination with chemotherapy has been shown to improve OS versus chemotherapy alone for advanced NSCLC patients without driver mutations, regardless of PD‐L1 expression. In the 2010s, immunotherapy, especially treatment with pembrolizumab (a monoclonal antibody of programmed cell death protein 1 antibody), altered the treatment landscape for NSCLC patients without driver mutations. However, even with platinum‐based chemotherapy, the 5‐year overall survival (OS) rate of these patients is still less than 7%. Platinum‐based chemotherapy is a traditional treatment for patients with advanced NSCLC. Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer comprising up to 85% of lung cancer cases. Lung cancer is one of the most frequently diagnosed cancers in the world with more than 2 million new cases diagnosed every year.Īs the largest developing country worldwide, China has more lung cancer diagnoses and fatalities than any other countries.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |